Table 1.
Characteristics of people with HIV (PWH) in active follow-up in CoRIS during the study period
| Variable | Total PWH n = 16 178 | PWH included in the serosurvey n = 1076 |
PWH not included in the serosurvey n = 15 102 |
p |
|---|---|---|---|---|
| Male sex at birth: n/with data (%) | 13 802/16 178 (85.3) | 947/1076 (88.0) | 12 855/15 102 (85.1) | 0.010 |
| Age | ||||
| Distribution: n/with data (%) | 0.279 | |||
| 18–34 | 3356/16 178 (20.7) | 235/1076 (21.8) | 3121/15 102 (20.7) | |
| 35–49 | 7939/16 178 (49.1) | 537/1076 (49.9) | 7402/15 102 (49.0) | |
| 50–64 | 4112/16 178 (25.4) | 264/1076 (24.5) | 3848/15 102 (25.5) | |
| ≥65 | 771/16 178 (4.8) | 40/1076 (3.7) | 731/15 102 (4.8) | |
| Median (Q1; Q3) yr | 44 (36; 52) | 43 (36; 51) | 44 (36:52) | 0.101 |
| Mechanism of HIV acquisition: n/with data (%) | < 0.001 | |||
| Men having sex with men | 10 013/15 717 (63.7) | 745/1030 (72.3) | 9268/14 687 (63.1) | |
| Heterosexual | 4430/15 717 (28.2) | 258/1030 (25.0) | 4172/14 687 (28.4) | |
| Injection drug use | 1118/15 717 (7.1) | 20/1030 (1.9) | 1098/14 687 (7.5) | |
| Other | 156/15 717 (1.0) | 7/1030 (0.7) | 149/14 687 (1.0) | |
| Country of birth: n/with data (%) | < 0.001 | |||
| Spain | 9480/16 112 (58.8) | 753/1075 (70.0) | 8727/15 037 (58.0) | |
| Latin American countries | 3457/16 112 (21.5) | 231/1075 (21.5) | 3226/15 037 (21.5) | |
| Other | 3175/16 112 (19.7) | 91/1075 (8.5) | 3084/15 037 (20.5) | |
| Level of education: n/with data (%) | < 0.001 | |||
| Compulsory education/no education | 4688/13 536 (34.6) | 257/951 (27.0) | 4431/12 585 (35.2) | |
| High school/university | 8581/13 536 (63.4) | 674/951 (70.9) | 7907/12 585 (62.8) | |
| Other | 267/13 536 (2.0) | 20/951 (2.1) | 247/12 585 (2.0) | |
| Comorbidities n/with data (%) | ||||
| Hypertension | 2402/16 178 (14.9) | 328/1076 (30.5) | 2074/15 102 (13.7) | < 0.001 |
| Chronic heart disease | 390/15 969 (2.4) | 29/1067 (2.7) | 361/14 902 (2.4) | 0.546 |
| Diabetes | 459/15 969 (2.9) | 25/1067 (2.3) | 434/14 902 (2.9) | 0.282 |
| History of non-AIDS-related cancer | 770/15 969 (4.8) | 42/1067 (3.9) | 728/14 902 (4.9) | 0.162 |
| Chronic kidney disease | 254/9298 (2.7) | 19/890 (2.1) | 235/8408 (2.8) | 0.251 |
| liver cirrhosis | 183/15 969 (1.2) | 6/1067 (0.6) | 177/14 902 (1.2) | 0.064 |
| Prior AIDS-defining conditions n/with data (%) | 2363/16 178 (14.6) | 132/1076 (12.3) | 2231/15 102 (14.8) | 0.025 |
| Last CD4+ count | ||||
| Distribution n/with data (%) | 0.606 | |||
| <350 | 1116/9836 (11.4) | 100/957 (10.4) | 1016/8879 (11.4) | |
| 350–499 | 1344/9836 (13.7) | 136/957 (14.2) | 1208/8879 (13.6) | |
| ≥500 | 7376/9836 (75.0) | 721/957 (75.3) | 6655/8879 (75.0) | |
| Median (Q1; Q3) cells/mm3 | 702 (499; 921) | 688 (500; 909) | 702 (499–922) | 0.477 |
| Last HIV-RNA load ≤50 copies/mm3n/with data (%) | 8996/10 005 (89.9) | 918/1004 (91.4) | 8078/9001 (89.7) | 0.092 |
| Antiretroviral therapy (N [t]RTI backbone) n/with data (%) | < 0.001 | |||
| TAF/FTC | 4289/14 587 (29.4) | 416/1062 (39.2) | 3873/13 525 (28.6) | |
| ABC/3TC | 3912/14 587 (26.8) | 279/1062 (26.3) | 3633/13 525 (26.9) | |
| TDF/FTC | 3036/14 587 (20.8) | 154/1062 (14.5) | 2882/13 525 (21.3) | |
| Other | 1927/14 587 (13.2) | 188/1062 (17.7) | 1739/13 525 (12.9) | |
| No antiretroviral therapy | 1423/14 587 (9.8) | 25/1062 (2.3) | 1398/13 525 (10.3) | |
| Antiretroviral therapy (third drug) | < 0.001 | |||
| NNRTI | 3434/14 587 (23.5) | 247/1062 (23.3) | 3187/13 525 (23.6) | |
| Protease inhibitor | 1451/14 587 (10.0) | 63/1062 (5.9) | 1388/13 525 (10.3) | |
| Integrase inhibitor | 6322/14 587 (43.3) | 530/1062 (49.9) | 5792/13 525 (42.8) | |
| Other | 1957/14 587 (13.4) | 197/1062 (18.6) | 1760/13 525 (13.0) | |
| No antiretroviral therapy | 1423/14 587 (9.8) | 25/1062 (2.3) | 1398/13 525 (10.3) | |
CoRIS, Spanish HIV Research Network Cohort; Q1, 1st quartile; Q3, 3rd quartile; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitors; TAF, tenofovir alafenamide; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; TDF; tenofovir disoproxil fumarate; NNRTI, non-nucleoside reverse transcriptase inhibitors.